Targeted Polyethylene Glycol-Linker-Drug Conjugate System

A next-generation polyethylene glycol-linker-drug conjugate system, enabling targeted delivery of various drug residues to specific cells or tissues through functional group modification of the polyethylene glycol residue.

The original patent disclosed a polyethylene glycol-linker-drug conjugate with limited delivery specificity. This new inventive concept addresses the need for targeted delivery of drugs to specific cells or tissues, thereby minimizing side effects and enhancing efficacy.

The polyethylene glycol-linker-drug conjugate system comprises a polyethylene glycol residue, a linking group, and a drug residue. The polyethylene glycol residue is modified to include at least one functional group for targeted delivery to specific cells or tissues. The linking group is selected from one or a combination of several of —(CH2)a—, —(CH2)aCO—, —(CH2)aOCO—, —(CH2)aNHCO—, —NH(CH2)aCO—, or —NH(CH2)aOCO—. The drug residue can be a polypeptide drug, a protein drug, a small molecule drug, a bi-specific antibody, a gene editing tool, or a combination therapy of at least two different drugs.

The new inventive concept introduces the modification of the polyethylene glycol residue with at least one functional group for targeted delivery, which is not disclosed in the original patent. This modification enables targeted delivery of various drug residues to specific cells or tissues, thereby providing a significant improvement over the original patent.

Alternative embodiments of the inventive concept include using different linking groups, modifying the polyethylene glycol residue with different functional groups, or using different drug residues. Variations of the inventive concept could include using different polymer backbones, modifying the drug residue for targeted delivery, or incorporating additional components for enhanced efficacy.

The targeted polyethylene glycol-linker-drug conjugate system has potential commercial applications in the treatment of various diseases, including cancer, genetic disorders, and inflammatory diseases. The market for targeted drug delivery systems is expected to grow significantly in the coming years, driven by the need for more effective and efficient treatments.